Ron Kagan

Summary

Affiliation: Quest Diagnostics
Country: USA

Publications

  1. ncbi Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples
    Ron M Kagan
    Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92675, USA
    AIDS 23:1602-5. 2009
  2. ncbi HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization
    Ron Kagan
    Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92690, USA
    AIDS Res Hum Retroviruses 20:1-9. 2004
  3. ncbi Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir
    Ron M Kagan
    Department of Infectious Diseases, Quest Diagnostics Inc, San Juan Capistrano, CA 92675, USA
    Protein Sci 14:1870-8. 2005
  4. ncbi Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region
    Milan Kozísek
    Gilead Sciences and IOCB Research Center, Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, v v i, Flemingovo 2, 166 10 Praha 6, Czech Republic
    J Virol 82:5869-78. 2008
  5. ncbi Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase
    Marleen C D G Huigen
    Department of Medical Microbiology, University Medical Center Utrecht, The Netherlands
    Retrovirology 5:20. 2008
  6. ncbi The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient
    Gary Blick
    Circle Medical LLC, Norwalk, CT 06851, USA
    J Infect Dis 195:1250-9. 2007
  7. ncbi New two-amino acid insertion near codon 70 of the HIV type 1 protease gene
    Mark A Winters
    Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    AIDS Res Hum Retroviruses 21:311-3. 2005
  8. ncbi Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors
    Mark A Winters
    Center for AIDS Research, Stanford University, Stanford, CA, USA
    Antivir Ther 10:363-6. 2005
  9. ncbi Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization
    Ron M Kagan
    Antivir Ther 9:827-8. 2004
  10. ncbi Structure-based phenotyping predicts HIV-1 protease inhibitor resistance
    Mark D Shenderovich
    Cengent Therapeutics Inc, 10929 Technology Place, San Diego, CA 92127, USA
    Protein Sci 12:1706-18. 2003

Collaborators

Detail Information

Publications10

  1. ncbi Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples
    Ron M Kagan
    Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92675, USA
    AIDS 23:1602-5. 2009
    ..Although the effect of K103S is unclear, additional position 138 substitutions seem important for etravirine susceptibility...
  2. ncbi HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization
    Ron Kagan
    Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92690, USA
    AIDS Res Hum Retroviruses 20:1-9. 2004
    ..Continued monitoring of ARV resistance prevalence, patterns, and utilization trends in clinical databases provides insight into the evolving relationship between clinical practice and ARV resistance...
  3. ncbi Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir
    Ron M Kagan
    Department of Infectious Diseases, Quest Diagnostics Inc, San Juan Capistrano, CA 92675, USA
    Protein Sci 14:1870-8. 2005
    ..The emergence of mutations at PR residue 47 strongly correlates with increasing prescriptions of LPV (Spearman correlation r(s) = 0.96, P < .0001)...
  4. ncbi Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region
    Milan Kozísek
    Gilead Sciences and IOCB Research Center, Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, v v i, Flemingovo 2, 166 10 Praha 6, Czech Republic
    J Virol 82:5869-78. 2008
    ..Amino acid insertions in the vicinity of the binding cleft therefore represent a novel mechanism of HIV resistance development...
  5. ncbi Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase
    Marleen C D G Huigen
    Department of Medical Microbiology, University Medical Center Utrecht, The Netherlands
    Retrovirology 5:20. 2008
    ..To unravel the role of two of these newly identified changes, E40F and K43E, we investigated their effect on viral drug susceptibility and replicative capacity...
  6. ncbi The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient
    Gary Blick
    Circle Medical LLC, Norwalk, CT 06851, USA
    J Infect Dis 195:1250-9. 2007
    ..The probable source of this HIV-1 (hereafter referred to as "CT01") and the development of a recombinant MDR HIV-1 in the source's partner (hereafter referred to as "CT02") are described...
  7. ncbi New two-amino acid insertion near codon 70 of the HIV type 1 protease gene
    Mark A Winters
    Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    AIDS Res Hum Retroviruses 21:311-3. 2005
    ..Susceptibility of this strain to protease inhibitors was similar to that of non-insert-containing strains with comparable resistance mutations and one or more other major PI mutations...
  8. ncbi Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors
    Mark A Winters
    Center for AIDS Research, Stanford University, Stanford, CA, USA
    Antivir Ther 10:363-6. 2005
    ..These results suggest that inserts in the NNRTI-binding pocket contribute to NNRTI resistance, but are tolerated only under specific genetic conditions...
  9. ncbi Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization
    Ron M Kagan
    Antivir Ther 9:827-8. 2004
  10. ncbi Structure-based phenotyping predicts HIV-1 protease inhibitor resistance
    Mark D Shenderovich
    Cengent Therapeutics Inc, 10929 Technology Place, San Diego, CA 92127, USA
    Protein Sci 12:1706-18. 2003
    ..666) with PhenoSense and Antivirogram phenotypes, respectively. The structural phenotyping predicted drug resistance of clinical HIV-1 PR variants with an accuracy approaching that of frequently used cell-based phenotypic assays...